1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Iran Pharmaceuticals and Healthcare Report Q2 2016

Iran Pharmaceuticals and Healthcare Report Q2 2016

  • April 2016
  • -
  • Business Monitor International
  • -
  • 92 pages

Includes 3 FREE quarterly updates

BMI View: With sanctions lifted, Iran has improving prospects of opening up to a wider diversity of tradingpartners and providing strategic opportunities for multinational pharmaceutical companies. Byreintegrating into the financial transaction system SWIFT, the import of pharmaceutical-related productswill ease and prevent future drug shortages. Both innovative and generic drugmakers will look to gain alocal presence within the country, given the growing demand for essential medicines and likelyimprovements to healthcare provision.

Headline Expenditure Projections

- Pharmaceuticals: IRR69.55tn (USD1.93bn) in 2015 to IRR78.95trn (USD1.97bn) in 2016; +13.5% inlocal currency terms and -2.2% in US dollar terms. Forecast upgraded from previous quarter.

- Healthcare: IRR810.99trn (USD22.53bn) in 2015 to IRR923.35trn (USD23.08bn) in 2016; +13.9% inlocal currency terms and +2.5% in US dollar terms. Forecast upgraded from previous quarter.

Table Of Contents

Iran Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Iran 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2012-2020) 18
Prescription Drug Market Forecast 19
Patented Drug Market Forecast 20
Generic Drug Market Forecast 21
OTC Market Forecast 22
Pharmaceutical Trade Forecast 23
Table: Pharmaceutical Trade Data And Forecasts (Iran 2014-2020) 26
Table: Pharmaceutical Trade Data And Forecasts local currency (Iran 2014-2020) 26
Industry Risk/Reward Index 27
Middle East and Africa Risk/Reward Index - Q2 2016 27
Iran Risk/Reward Index 34
Rewards 34
Risks 35
Regulatory Review 36
Intellectual Property Regime 38
Pricing and Reimbursement Regime 40
Market Overview 42
Healthcare Sector 43
Table: Healthcare Resources (Iran 2010-2015) 45
Table: Healthcare Personnel (Iran 2010-2015) 46
Table: Healthcare Activity (Iran 2010-2015) 46
Research and Development 49
Clinical Trials 53
Epidemiology 53
Competitive Landscape 57
Research-Based Industry 57
Table: Multinational Company Activity 59
Generic Drugmakers 61
Table: Leading Drug Manufacturers, Iran - To March 2009 61
Pharmaceutical Distribution 64
Table: Leading Distributors, Iranian Year To March 20 2008 65
Pharmaceutical Retail Sector 65
Table: Tehran Stock Exchange - Listed Pharmaceutical Companies As Of November 2015 66
Company Profile 67
Caspian Tamin Pharmaceutical Company 67
Darou Pakhsh 70
Exir Pharmaceuticals 73
Pars Darou 76
Zahravi Pharmaceutical Company 78
Demographic Forecast 81
Table: Population Headline Indicators (Iran 1990-2025) 82
Table: Key Population Ratios (Iran 1990-2025) 82
Table: Urban/Rural Population and Life Expectancy (Iran 1990-2025) 83
Table: Population By Age Group (Iran 1990-2025) 83
Table: Population By Age Group % (Iran 1990-2025) 84
Glossary 86
Methodology 88
Pharmaceutical Expenditure Forecast Model 88
Healthcare Expenditure Forecast Model 88
Notes On Methodology 89
Risk/Reward Index Methodology 90
Index Overview 91
Table: Pharmaceutical Risk/Reward Index Indicators 91
Indicator Weightings 92

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.